Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Survodutide

SYNCHRONIZE-1

Boehringer Ingelheim · Phase 3 · Completed · Enrollment 726

NCT06066515

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Survodutide 3.6 mgn/rn/rn/rn/r
Survodutide 6.0 mgn/rn/rn/rn/r
Placebon/rn/rn/rn/r

Not shown

  • Survodutide 3.6 mg: endpoint not reported
  • Survodutide 6.0 mg: endpoint not reported
  • Placebo: endpoint not reported